Loading patent…
AssigneeAgilent Technologies, Inc.
InventorsMorten Draeby SORENSEN, Tine HAGEDORN-OLSEN, Lasse RAMSGAARD, Morten Alder SCHULZ
Estimating the term…
In alternative embodiments, provided are chimeric, synthetic or recombinant anti-human homeobox NKX-2.1 (also called NK2 homeobox 1, or thyroid transcription factor 1 (TTF-1)) protein antibodies (Abs), including products of manufacture and kits comprising them, and methods for making and using them, including for example their use in the detection or diagnosis, and treatment, of a cancer. In alternative embodiments, anti-NKX-2.1 (TTF-1) antibodies as provided herein are used together with an agent for determining whether NKX-2.1 (TTF-1) expression or activity is present, reduced or absent; or an Ab, or antigen (Ag) binding fragment or protein (ABP) thereof, or monomeric or dimeric ABP, as provided herein is less sensitive (or binds with lower affinity) in specific binding to a lung squamous cell carcinoma cell than specifically binding to an adenocarcinoma cell, thereby resulting in fewer lung squamous cell carcinoma false positives and better positive identification of lung adenocarcinoma.
An isolated or purified antibody (Ab), or synthetic or recombinant Ab, or antigen (Ag) binding fragment thereof, or monomeric or dimeric antigen binding protein (ABP), capable of specifically binding a human homeobox NKX-2.1 (also called NK2 homeobox 1, or thyroid transcription factor 1 (TTF-1)) protein or polypeptide,
(canceled)
(canceled)
An isolated or purified antibody (Ab), or synthetic or recombinant Ab, or antigen (Ag) binding fragment thereof comprising:
Dependencies are inferred from the claim text.